Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of hypertension in CKD patients with azilsartan/chlorthalidone vs olmesartan/hydrochlorothiazide.

× No keyword cloud information.

12 in total

1. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors: Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal: Lancet Date: 2005 Sep 10-16 Impact factor: 79.321

2. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.

Authors: Michael E Ernst; Barry L Carter; Chris J Goerdt; Jennifer J G Steffensmeier; Beth Bryles Phillips; M Bridget Zimmerman; George R Bergus
Journal: Hypertension Date: 2006-01-23 Impact factor: 10.190

3. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors: Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal: Lancet Date: 2004-06-19 Impact factor: 79.321

4. Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.

Authors: George L Bakris; Lin Zhao; Stuart Kupfer; Attila Juhasz; Michie Hisada; Eric Lloyd; Suzanne Oparil
Journal: J Clin Hypertens (Greenwich) Date: 2018-03-04 Impact factor: 3.738

5. Treatment of hypertension in CKD patients with azilsartan/chlorthalidone vs olmesartan/hydrochlorothiazide.

Authors: Walter M van der Merwe
Journal: J Clin Hypertens (Greenwich) Date: 2018-03-04 Impact factor: 3.738

6. Why are we still using hydrochlorothiazide?

Authors: Clive Rosendorff
Journal: J Clin Hypertens (Greenwich) Date: 2011-12-01 Impact factor: 3.738

7. Determining the relative antihypertensive potency and relative cardiovascular risk reduction associated with different thiazide and thiazide-type diuretics.

Authors: Jan N Basile; Michael J Bloch
Journal: J Clin Hypertens (Greenwich) Date: 2013-02-27 Impact factor: 3.738

8. The comparative effectiveness of hydrochlorothiazide and chlorthalidone in an observational cohort of veterans.

Authors: Brian C Lund; Michael E Ernst
Journal: J Clin Hypertens (Greenwich) Date: 2012-09 Impact factor: 3.738

9. Comparing clinical effectiveness and drug toxicity with hydrochlorothiazide and chlorthalidone using two potency ratios in a managed care population.

Authors: Joseph J Saseen; Vahram Ghushchyan; Kavita V Nair
Journal: J Clin Hypertens (Greenwich) Date: 2014-12-15 Impact factor: 3.738

Review 10. Hypertension, renal disease, and drug considerations.

Authors: Domenic A Sica
Journal: J Clin Hypertens (Greenwich) Date: 2004-10 Impact factor: 3.738

1 in total

1. Treatment of hypertension in CKD patients with azilsartan/chlorthalidone vs olmesartan/hydrochlorothiazide.

Authors: Walter M van der Merwe
Journal: J Clin Hypertens (Greenwich) Date: 2018-03-04 Impact factor: 3.738

1 in total